Clinical Trial Update: Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of berzosertib and topotecan in relapsed platinum-resistant small-cell lung cancer has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Berzosertib (berzosertib)
• Topotecan (topotecan)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Small-cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-26